These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Oncogenic fusion protein FGFR2-PPHLN1: Requirements for biological activation, and efficacy of inhibitors. Li F; Meyer AN; Peiris MN; Nelson KN; Donoghue DJ Transl Oncol; 2020 Dec; 13(12):100853. PubMed ID: 32854034 [TBL] [Abstract][Full Text] [Related]
6. Typing FGFR2 translocation determines the response to targeted therapy of intrahepatic cholangiocarcinomas. Pu X; Ye Q; Cai J; Yang X; Fu Y; Fan X; Wu H; Chen J; Qiu Y; Yue S Cell Death Dis; 2021 Mar; 12(3):256. PubMed ID: 33692336 [TBL] [Abstract][Full Text] [Related]
7. Molecular heterogeneity in the novel fusion gene Okuda T; Taki T; Nishida K; Chinen Y; Nagoshi H; Sakakura C; Taniwaki M Oncol Lett; 2017 Jan; 13(1):215-221. PubMed ID: 28123544 [TBL] [Abstract][Full Text] [Related]
8. Identification and In-Depth Analysis of the Novel FGFR2-NDC80 Fusion in a Cholangiocarcinoma Patient: Implication for Therapy. Scheiter A; Keil F; Lüke F; Grosse J; Verloh N; Opitz S; Schlosser S; Kandulski A; Pukrop T; Dietmaier W; Evert M; Calvisi DF; Utpatel K Curr Oncol; 2021 Mar; 28(2):1161-1169. PubMed ID: 33800328 [TBL] [Abstract][Full Text] [Related]
9. Kao XM; Zhu X; Zhang JL; Chen SQ; Fan CG World J Clin Cases; 2021 Aug; 9(23):6867-6871. PubMed ID: 34447836 [TBL] [Abstract][Full Text] [Related]
10. Low-level clonal FGFR2 amplification defines a unique molecular subtype of intrahepatic cholangiocarcinoma in a Chinese population. Pu XH; Ye Q; Yang J; Wu HY; Ding XW; Shi J; Mao L; Fan XS; Chen J; Qiu YD; Huang Q Hum Pathol; 2018 Jun; 76():100-109. PubMed ID: 29514108 [TBL] [Abstract][Full Text] [Related]
11. Incidence of FGFR2 Amplification and FGFR2 Fusion in Patients with Metastatic Cancer Using Clinical Sequencing. Hyung S; Han B; Jung J; Kim ST; Hong JY; Park SH; Zang DY; Park JO; Park YS; Kim KM; Kang WK; Lee J J Oncol; 2022; 2022():9714570. PubMed ID: 35342406 [TBL] [Abstract][Full Text] [Related]
12. Advances in chromosomal translocations and fusion genes in sarcomas and potential therapeutic applications. Xiao X; Garbutt CC; Hornicek F; Guo Z; Duan Z Cancer Treat Rev; 2018 Feb; 63():61-70. PubMed ID: 29247978 [TBL] [Abstract][Full Text] [Related]
13. Acquired resistance to LY2874455 in FGFR2-amplified gastric cancer through an emergence of novel FGFR2-ACSL5 fusion. Kim SY; Ahn T; Bang H; Ham JS; Kim J; Kim ST; Jang J; Shim M; Kang SY; Park SH; Min BH; Lee H; Kang WK; Kim KM; Park W; Lee J Oncotarget; 2017 Feb; 8(9):15014-15022. PubMed ID: 28122360 [TBL] [Abstract][Full Text] [Related]
14. Novel molecular pathways elicited by mutant FGFR2 may account for brain abnormalities in Apert syndrome. Yeh E; Fanganiello RD; Sunaga DY; Zhou X; Holmes G; Rocha KM; Alonso N; Matushita H; Wang Y; Jabs EW; Passos-Bueno MR PLoS One; 2013; 8(4):e60439. PubMed ID: 23593218 [TBL] [Abstract][Full Text] [Related]
15. Ying X; Tu J; Wang W; Li X; Xu C; Ji J Onco Targets Ther; 2019; 12():9303-9307. PubMed ID: 31807010 [TBL] [Abstract][Full Text] [Related]
16. FGFR2 and WDR11 are neighboring oncogene and tumor suppressor gene on human chromosome 10q26. Katoh M; Katoh M Int J Oncol; 2003 May; 22(5):1155-9. PubMed ID: 12684685 [TBL] [Abstract][Full Text] [Related]
17. TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma. Goyal L; Shi L; Liu LY; Fece de la Cruz F; Lennerz JK; Raghavan S; Leschiner I; Elagina L; Siravegna G; Ng RWS; Vu P; Patra KC; Saha SK; Uppot RN; Arellano R; Reyes S; Sagara T; Otsuki S; Nadres B; Shahzade HA; Dey-Guha I; Fetter IJ; Baiev I; Van Seventer EE; Murphy JE; Ferrone CR; Tanabe KK; Deshpande V; Harding JJ; Yaeger R; Kelley RK; Bardelli A; Iafrate AJ; Hahn WC; Benes CH; Ting DT; Hirai H; Getz G; Juric D; Zhu AX; Corcoran RB; Bardeesy N Cancer Discov; 2019 Aug; 9(8):1064-1079. PubMed ID: 31109923 [TBL] [Abstract][Full Text] [Related]
18. Chromosomal translocations in cancer and their relevance for therapy. Taki T; Taniwaki M Curr Opin Oncol; 2006 Jan; 18(1):62-8. PubMed ID: 16357566 [TBL] [Abstract][Full Text] [Related]